^
Association details:
Biomarker:FGFR2 fusion
Cancer:Solid Tumor
Drug:zoligratinib (Debio 1347) (FGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.

Published date:
05/13/2020
Excerpt:
Debio 1347 at the recommended dose of 80 mg qd was generally well tolerated and showed signs of activity in solid tumors harboring an FGFR fusion.
DOI:
10.1200/JCO.2020.38.15_suppl.3603